STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec, said its analytical service unit (ASU) in Shanghai and active pharmaceutical ingredient (API) process R&D and manufacturing facility in Changzhou, have passed two inspections from the U.S. FDA within the same week, with no Form 483s issued.
 
“It’s a point of great pride that our quality systems allow us to be inspected at short notice by any applicable regulatory agency in the world. In this case, we received two separate inspection notices from FDA only seven days and five days in advance of the inspections, respectively. It’s an endorsement of the real time monitoring and quality culture we run across all parts of the company,” said Mei Hao, vice president of quality, WuXi STA. “It’s another key example of the rigorous nature of our global standard quality systems. It is also another milestone for our platform, and in our efforts to have geographically integrated capabilities for both drug product and drug substance.”
 
WuXi STA has now passed seven inspections from the U.S. FDA since 2013, producing branded drugs marketed in 95 countries. Its analytical service unit provides clients with a full spectrum of analytical method development, validation and testing services from preclinical to commercial. The Changzhou facility with over 1,700,000 square feet has established a variety of new technology platforms such as spray dried dispersion, continuous processing (flow chemistry), oligonucleotides and peptides. It successfully completed the first U.S. FDA inspection in 2018.